AU2018231405B2 - MR1 restricted T cell receptors for cancer immunotherapy - Google Patents

MR1 restricted T cell receptors for cancer immunotherapy Download PDF

Info

Publication number
AU2018231405B2
AU2018231405B2 AU2018231405A AU2018231405A AU2018231405B2 AU 2018231405 B2 AU2018231405 B2 AU 2018231405B2 AU 2018231405 A AU2018231405 A AU 2018231405A AU 2018231405 A AU2018231405 A AU 2018231405A AU 2018231405 B2 AU2018231405 B2 AU 2018231405B2
Authority
AU
Australia
Prior art keywords
ser
leu
val
thr
ala
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018231405A
Other languages
English (en)
Other versions
AU2018231405A1 (en
Inventor
Gennaro De Libero
Marco LEPORE
Lucia Mori
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universitaet Basel
Original Assignee
Universitaet Basel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universitaet Basel filed Critical Universitaet Basel
Publication of AU2018231405A1 publication Critical patent/AU2018231405A1/en
Application granted granted Critical
Publication of AU2018231405B2 publication Critical patent/AU2018231405B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2307—Interleukin-7 (IL-7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2315—Interleukin-15 (IL-15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU2018231405A 2017-03-07 2018-03-07 MR1 restricted T cell receptors for cancer immunotherapy Active AU2018231405B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP17159754.5 2017-03-07
EP17159754 2017-03-07
EP17179309 2017-07-03
EP17179309.4 2017-07-03
PCT/EP2018/055620 WO2018162563A1 (en) 2017-03-07 2018-03-07 Mr1 restricted t cell receptors for cancer immunotherapy

Publications (2)

Publication Number Publication Date
AU2018231405A1 AU2018231405A1 (en) 2019-09-26
AU2018231405B2 true AU2018231405B2 (en) 2024-02-08

Family

ID=61563412

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018231405A Active AU2018231405B2 (en) 2017-03-07 2018-03-07 MR1 restricted T cell receptors for cancer immunotherapy

Country Status (9)

Country Link
EP (2) EP3592839B1 (enExample)
JP (2) JP7233103B2 (enExample)
KR (1) KR20190126332A (enExample)
CN (1) CN110462024B (enExample)
AU (1) AU2018231405B2 (enExample)
CA (1) CA3054758A1 (enExample)
IL (1) IL268813A (enExample)
WO (1) WO2018162563A1 (enExample)
ZA (1) ZA201905579B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4099015A1 (en) 2016-06-10 2022-12-07 Gadeta B.V. Novel method for identifying deltat-cell (or gammat-cell) receptor chains or parts thereof that mediate an anti-tumour or an anti-infective response
AU2018268087B2 (en) 2017-05-18 2022-03-17 Umc Utrecht Holding B.V. Compositions and methods for cell targeting therapies
GB201717578D0 (en) 2017-10-26 2017-12-13 Univ College Cardiff Consultants Ltd Novel T-cell receptor
JP7469807B2 (ja) * 2018-04-19 2024-04-17 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム Ｍａｇｅ－ｂ２特異性を有するｔ細胞受容体およびその使用
BR112021003996A2 (pt) * 2018-09-12 2021-05-25 Universität Basel receptores de célula t restritos à mr1 para imunoterapia contra o câncer
SG11202105975SA (en) * 2018-12-06 2021-07-29 Guangdong Tcrcure Biopharma Technology Co Ltd Combinational tcr-t cell therapy targeting tumor antigens, tgf-beta, and immune checkpoints
WO2022118043A1 (en) 2020-12-03 2022-06-09 Enara Bio Limited Novel protein-ligand complex
WO2022248881A1 (en) 2021-05-28 2022-12-01 Enara Bio Limited Novel protein-ligand complex
KR20230088292A (ko) * 2021-12-10 2023-06-19 주식회사 유틸렉스 MR1 제한적 Panck T 세포 및 이의 제조방법
WO2023148494A1 (en) * 2022-02-03 2023-08-10 University College Cardiff Consultants Limited Novel t-cell receptor
CN119587561B (zh) * 2024-12-09 2025-11-28 新乡医学院 THP在制备增强Vγ9Vδ2 T细胞抗肿瘤疗效的药物中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2899269A1 (en) * 2012-07-25 2015-07-29 National University Corporation University Of Toyama Method for cloning t cell receptor

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2089229C (en) * 1992-02-14 2010-04-13 Alejandro A. Aruffo Cd40cr receptor and ligands therefor
US7829289B2 (en) * 2002-05-14 2010-11-09 Institut National De La Sante Et De Recherche Medicale T cell subpopulation regulating gut immunity
US10000546B2 (en) * 2013-03-13 2018-06-19 Health Research, Inc. Compositions and method for use of recombinant T cell receptors for direct recognition of tumor antigen
WO2015149130A1 (en) * 2014-04-01 2015-10-08 The University Of Queensland Immunological reagents and uses therefor

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2899269A1 (en) * 2012-07-25 2015-07-29 National University Corporation University Of Toyama Method for cloning t cell receptor

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LARS KJER-NIELSEN ET AL: "MR1 presents microbial vitamin B metabolites to MAIT cells", NATURE, 2012 , 491(7426):717-723, DOI: 10.1038/nature11605 *

Also Published As

Publication number Publication date
WO2018162563A1 (en) 2018-09-13
CN110462024A (zh) 2019-11-15
EP4273233A3 (en) 2023-11-15
ZA201905579B (en) 2024-08-28
JP2020527036A (ja) 2020-09-03
KR20190126332A (ko) 2019-11-11
AU2018231405A1 (en) 2019-09-26
IL268813A (en) 2019-10-31
JP7515209B2 (ja) 2024-07-12
CN110462024B (zh) 2024-08-09
CA3054758A1 (en) 2018-09-13
JP2023058659A (ja) 2023-04-25
EP3592839C0 (en) 2023-07-05
EP3592839A1 (en) 2020-01-15
EP4273233A2 (en) 2023-11-08
EP3592839B1 (en) 2023-07-05
JP7233103B2 (ja) 2023-03-06

Similar Documents

Publication Publication Date Title
AU2018231405B2 (en) MR1 restricted T cell receptors for cancer immunotherapy
US20240301024A1 (en) Use of icos-based cars to enhance antitumor activity and car persistence
KR102823603B1 (ko) 면역요법을 위한 t 세포 수용체
KR20140127816A (ko) 암의 치료에 유용한 t 세포의 지속성 집단을 생성시키기 위한 조성물 및 방법
US20230295319A1 (en) Chimeric antigen receptors and uses thereof
US11702459B2 (en) MR1 restricted T cell receptors for cancer immunotherapy
KR20210057750A (ko) 암 면역치료요법을 위한 mr1 제한된 t 세포 수용체
JP2022513390A (ja) Ｔｃｒ及びペプチド
JP2017522859A (ja) グリピカン３に特異的なｔ細胞受容体、及び肝細胞癌の免疫療法のためのその使用
JP2023040034A (ja) 耐性を誘導するための操作された細胞
US20240002465A1 (en) Mr1 restricted t cell receptors for cancer immunotherapy
CA3141210A1 (en) Modified nk-92 cells, and therapeutic and diagnostic uses thereof
WO2026003364A1 (en) Chimeric coreceptors
WO2023006828A1 (en) Antigen binding proteins specifically binding ct45
CN117980324A (zh) 特异性结合ct45的抗原结合蛋白
TW202132326A (zh) Hla限制性hormad1 t細胞受體及其用途

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)